Compare LFS & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFS | INCR |
|---|---|---|
| Founded | 2001 | 1994 |
| Country | Japan | Israel |
| Employees | 1055 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.2M | 47.4M |
| IPO Year | N/A | 2021 |
| Metric | LFS | INCR |
|---|---|---|
| Price | $2.32 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 722.6K | 10.4K |
| Earning Date | 04-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $69.54 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | $25.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $0.68 |
| 52 Week High | $12.49 | $1.77 |
| Indicator | LFS | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.89 | 46.28 |
| Support Level | $2.16 | $0.85 |
| Resistance Level | $2.74 | $0.99 |
| Average True Range (ATR) | 0.30 | 0.05 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 18.78 | 42.08 |
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children. The company focuses on covering 13 sports like soccer, basketball, and dance and in child athletic development, club activity management for schools, and social businesses like elderly care.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.